{"DataElement":{"publicId":"3574978","version":"1","preferredName":"Patient Cisplatin Sensitivity Level Category","preferredDefinition":"Term to signify the degree of cisplatin (Platinol) sensitivity a patient has based on time to disease progression.","longName":"PT_CISPLAT_SEN_CAT","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3574973","version":"1","preferredName":"Patient Cisplatin Resistance Sensitivity Level","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04)_A Resistance Process consists of activities of biologic molecules or complexes involved in processes that maintain immunity to, or counteract, defeat, or withstand the effects of, an antagonistic agent._Sensitivity; the ability to respond to physical stimuli or to register small physical amounts or differences._A position on a scale measuring intensity, quality, or amount.  (NCI)","longName":"CISPLAT_RES_SENS_LVL","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3574971","version":"1","preferredName":"Cisplatin Resistance Process Sensitivity Level","preferredDefinition":"An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04):A Resistance Process consists of activities of biologic molecules or complexes involved in processes that maintain immunity to, or counteract, defeat, or withstand the effects of, an antagonistic agent.:Sensitivity; the ability to respond to physical stimuli or to register small physical amounts or differences.:A position on a scale measuring intensity, quality, or amount.  (NCI)","longName":"C376:C41546:C25201:C25554","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Resistance Process","conceptCode":"C41546","definition":"A Resistance Process consists of activities of biologic molecules or complexes involved in processes that maintain immunity to, or counteract, defeat, or withstand the effects of, an antagonistic agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Sensitivity","conceptCode":"C25201","definition":"The ability to respond to physical stimuli or to register small physical amounts or differences.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Level","conceptCode":"C25554","definition":"A position on a scale measuring intensity, quality, or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C87DA437-538D-9B2A-E040-BB89AD433062","latestVersionIndicator":"Yes","beginDate":"2012-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-30","modifiedBy":"ONEDATA","dateModified":"2012-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C87DA437-539E-9B2A-E040-BB89AD433062","latestVersionIndicator":"Yes","beginDate":"2012-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-30","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3574975","version":"1","preferredName":"Cisplatin Sensitivity Category","preferredDefinition":"An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04)_A measure of the minimum change in an input signal that an instrument can detect._Category; used informally to mean a class of things.","longName":"CISPLAT_SEN_CAT","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"35","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Platinum very sensitive","valueDescription":"Cisplatinum (Platinol very sensitive","ValueMeaning":{"publicId":"3574976","version":"1","preferredName":"Cisplatinum (Platinol very sensitive","longName":"3574976","preferredDefinition":"Disease progression > 12 months after last platinum treatment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C87DA437-53D7-9B2A-E040-BB89AD433062","latestVersionIndicator":"Yes","beginDate":"2012-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C87DA437-53F0-9B2A-E040-BB89AD433062","beginDate":"2012-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-30","modifiedBy":"ONEDATA","dateModified":"2012-08-30","deletedIndicator":"No"},{"value":"Platinum intermediate sensitivity","valueDescription":"Cisplatinum (Platinol) intermediate sensitivity","ValueMeaning":{"publicId":"3574977","version":"1","preferredName":"Cisplatinum (Platinol) intermediate sensitivity","longName":"3574977","preferredDefinition":"Disease progression 6-12 months after last platinum treatment","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C87DA437-53FA-9B2A-E040-BB89AD433062","latestVersionIndicator":"Yes","beginDate":"2012-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C87DA437-5413-9B2A-E040-BB89AD433062","beginDate":"2012-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-30","modifiedBy":"ONEDATA","dateModified":"2012-08-30","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3574974","version":"1","preferredName":"Cisplatin Sensitivity Category","preferredDefinition":"An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04):A measure of the minimum change in an input signal that an instrument can detect.:Category; used informally to mean a class of things.","longName":"C376:C68816:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Sensitivity","conceptCode":"C68816","definition":"A measure of the minimum change in an input signal that an instrument can detect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C87DA437-53B3-9B2A-E040-BB89AD433062","latestVersionIndicator":"Yes","beginDate":"2012-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-30","modifiedBy":"ONEDATA","dateModified":"2012-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C87DA437-53C4-9B2A-E040-BB89AD433062","latestVersionIndicator":"Yes","beginDate":"2012-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-30","modifiedBy":"ONEDATA","dateModified":"2012-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2812367","version":"1","longName":"caBIG","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2183535","version":"1","longName":"Clinical Trial Mgmt Systems","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2812625","version":"1","longName":"CTMS C3D Adopter Sites","context":"NCIP"},{"publicId":"2811715","version":"1","longName":"Duke University","context":"NCIP"},{"publicId":"2812724","version":"1","longName":"Duke U New CDEs","context":"NCIP"}]},{"publicId":"3886752","version":"1","longName":"For Review","context":"DCI","ClassificationSchemeItems":[{"publicId":"3891931","version":"1","longName":"For Review","context":"DCI"}]}],"AlternateNames":[{"name":"DCI","type":"USED_BY","context":"DCI"}],"ReferenceDocuments":[{"name":"If platinum sensitive, platin","type":"Preferred Question Text","description":"If platinum sensitive, platinum sensitivity level (choose one)","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C87DA437-541D-9B2A-E040-BB89AD433062","latestVersionIndicator":"Yes","beginDate":"2012-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-30","modifiedBy":"ZHANGWE","dateModified":"2013-09-13","changeDescription":"Curated to support Duke University GYN trial","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}